Lung MAP offers several advantages over traditional clinical trials:
Efficiency: By testing multiple therapies within a single protocol, Lung MAP reduces the time and resources needed to bring new treatments to the market. Personalization: The trial uses genetic profiling to tailor treatments to individual patients, thereby increasing the chances of success. Collaboration: The initiative brings together various stakeholders including government agencies, pharmaceutical companies, and research institutions, fostering a collaborative environment for cancer research.
